

VU Research Portal

Application of TLR agonists in cancer immunotherapy: from late to early, from systemic to local

Koster, B.D.

2020

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Koster, B. D. (2020). *Application of TLR agonists in cancer immunotherapy: from late to early, from systemic to local*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Table of contents

Chapter 1	General introduction and outline of this thesis <i>Curr. Opin. Oncol. 2015 Nov;27(6):482-8</i>	9
Chapter 2	Autologous tumor cell vaccination combined with systemic CpG-B and IFNα promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: A phase II trial <i>Cancer Immunol Immunother. 2019 Jun;68(6).</i>	27
Chapter 3	High and interrelated rates of PD-L1⁺CD14⁺ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer <i>Cancer Immunol Res. 2015;3:48–58</i>	57
Chapter 4	Melanoma sequentially suppresses different DC subsets in the sentinel lymph node, affecting disease spread and recurrence <i>Cancer Immunol Res. 2017 Nov;5(11):969-977.</i>	87
Chapter 5	Response: Breslow thickness and excision interval affect the activation state of Langerhans cells in melanoma sentinel lymph nodes <i>Blood. 2012;119:4809–10.</i>	117
Chapter 6	T cell infiltration upon local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A⁺CD141⁺ cDC1 and CD14⁺ antigen-presenting cell recruitment <i>Manuscript in Preparation 2020.</i>	125
Chapter 7	Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/ CD141⁺ dendritic cells and enhanced cross-presentation <i>Cancer Immunol Res. 2015;3:495–505.</i>	161

Chapter 8	Local adjuvant treatment with low-dose CpG-B offers durable protection against disease recurrence in clinical stage I–II melanoma: data from two randomized phase II trials	191
	<i>Clin Cancer Res. 2017;23:5679–86.</i>	
Chapter 9	In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma	215
	<i>Oncoimmunology. 2020;9:1708066.</i>	
Chapter 10	Summarizing discussion and future directions	231
	<i>Cancer Immunol Immunother. 2019;68:1681–8.</i>	
Appendices	Nederlandse Samenvatting	255
	Curriculum Vitae	261
	Dankwoord	263